Akebia TherapeuticsAKBA +10.14%49 Quick Ratio is 1.33 as of Mar. 2026, which is 5% below its 10-year median of 1.40. GuruFocus rates AKBA with a GF Score™ of 49/100 and a GF Value™ of $1.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 994 Drug Manufacturers companies, Akebia Therapeutics ranks worse than 53.62% on this metric.
Akebia Therapeutics has a quick ratio of 1.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for Akebia Therapeutics's Quick Ratio or its related term are showing as below:
AKBA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.82 Med: 1.4 Max: 9.2
Current: 1.33
During the past 13 years, Akebia Therapeutics's highest Quick Ratio was 9.20. The lowest was 0.82. And the median was 1.40.
AKBA's Quick Ratio is ranked worse than 53.62% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs AKBA: 1.33
Akebia Therapeutics (NAS:AKBA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Akebia Therapeutics Quick Ratio Related Terms
Akebia Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Akebia Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (AKBA) has a Quick Ratio of 1.33 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Akebia Therapeutics and its competitors. This is near median its historical median of 1.40. Over the past decade, Akebia Therapeutics' Quick Ratio has ranged from 0.82 to 9.20. According to the industry distribution chart, Akebia Therapeutics ranks #533 out of 994 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is Akebia Therapeutics' Quick Ratio too high?
Akebia Therapeutics' current Quick Ratio of 1.33 is near median its 10-year median of 1.40. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 9.20. The Drug Manufacturers industry median Quick Ratio is 1.45. Akebia Therapeutics' value of 1.33 is 8.3% below this industry median. Based on the distribution chart, Akebia Therapeutics ranks #533 out of 994 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Quick Ratio compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #533 out of 994 companies for Quick Ratio. This places Akebia Therapeutics in the lower half of its industry. The industry median Quick Ratio is 1.45. Akebia Therapeutics' value of 1.33 is 8.3% below this benchmark. Historically, Akebia Therapeutics' own Quick Ratio has ranged from 0.82 to 9.20 over the past decade. While the company's 10-year median is 1.40 vs. the industry median of 1.45, Akebia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Quick Ratio of 1.33 is 8.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Quick Ratio is 1.33, which is near median its own 10-year median of 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (AKBA) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.31, compared to a current price of $1.14 — trading 13% below its estimated fair value. The current Quick Ratio is 1.33, which is near median its 10-year median of 1.40 and 8.3% below the Drug Manufacturers industry median of 1.45. Akebia Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Akebia Therapeutics (AKBA), the current Quick Ratio is 1.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (AKBA) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of $1.14 is trading 13% below its estimated GF Value™ of $1.31.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for AKBA:
Quick Ratio: 1.33 (near median its 10-year median of 1.40)
GF Value™: $1.31 vs. price of $1.14 (13% below fair value)
Industry Position: 8.3% below the Drug Manufacturers median (#533 of 994)
No single metric tells the full story. See the AKBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
49GF Score
Get the complete analysis for AKBA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKBA has been successfully added to your 
